Premier Path Wealth Partners LLC Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Premier Path Wealth Partners LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 8.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 558 shares of the biopharmaceutical company’s stock after purchasing an additional 42 shares during the quarter. Premier Path Wealth Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $537,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $932,571,000. FMR LLC lifted its stake in Regeneron Pharmaceuticals by 7.3% during the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after purchasing an additional 669,517 shares during the last quarter. International Assets Investment Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 76,169.5% in the 4th quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after buying an additional 590,314 shares during the period. Global Assets Advisory LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at approximately $339,594,000. Finally, First Trust Advisors LP increased its position in Regeneron Pharmaceuticals by 115.2% in the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after buying an additional 195,902 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on REGN shares. Truist Financial restated a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Barclays boosted their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Bank of America raised their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Finally, Evercore ISI initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 target price for the company. One analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $989.36.

Check Out Our Latest Analysis on REGN

Insider Buying and Selling

In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Marion Mccourt sold 358 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $967.50, for a total value of $346,365.00. Following the completion of the transaction, the executive vice president now directly owns 13,431 shares of the company’s stock, valued at $12,994,492.50. The disclosure for this sale can be found here. In the last three months, insiders sold 55,925 shares of company stock valued at $54,616,836. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ REGN traded up $6.68 during trading hours on Tuesday, hitting $993.95. 331,610 shares of the company traded hands, compared to its average volume of 483,594. The company’s 50 day moving average price is $943.60 and its 200 day moving average price is $912.25. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $998.33. The stock has a market capitalization of $109.52 billion, a price-to-earnings ratio of 29.36, a price-to-earnings-growth ratio of 2.02 and a beta of 0.17. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Read More

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.